Incidence and outcome of SARS-CoV-2 infection in patients with monoclonal gammopathy of undetermined significance: a case-control study
Open Access
- 4 November 2021
- journal article
- letter
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 107 (2) , 555-557
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- SARS-CoV-2 Vaccines in Patients With Multiple MyelomaHemaSphere, 2021
- Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data setBlood, 2020
- Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortalityBlood Cancer Journal, 2020
- Clinical characteristics and outcome of multiple myeloma patients with concomitant COVID-19 at Comprehensive Cancer Centers in GermanyHaematologica, 2020
- A case series of Monoclonal Gammopathy of Undetermined Significance and COVID‐19British Journal of Haematology, 2020
- Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in ItalyJAMA, 2020
- Long-Term Follow-up of Monoclonal Gammopathy of Undetermined SignificanceNew England Journal of Medicine, 2018
- The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma NetworkHaematologica, 2014
- Monoclonal gammopathy of undetermined significance and risk of infections: a population-based studyHaematologica, 2011
- Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based studyHaematologica, 2009